1102 related articles for article (PubMed ID: 30075406)
1. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
Fragomeni MO; Bichuetti DB; Oliveira EML
Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
[TBL] [Abstract][Full Text] [Related]
2. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
[TBL] [Abstract][Full Text] [Related]
3. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.
Ayzenberg I; Schöllhammer J; Hoepner R; Hellwig K; Ringelstein M; Aktas O; Kümpfel T; Krumbholz M; Trebst C; Paul F; Pache F; Obermann M; Zeltner L; Schwab M; Berthele A; Jarius S; Kleiter I;
J Neurol; 2016 Mar; 263(3):575-82. PubMed ID: 26810718
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.
Healy BC; Glanz BI; Zurawski JD; Mazzola M; Chitnis T; Weiner HL
J Neurol Sci; 2018 Nov; 394():127-131. PubMed ID: 30248571
[TBL] [Abstract][Full Text] [Related]
7. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
8. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?
Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
Mult Scler; 2012 Oct; 18(10):1480-3. PubMed ID: 22354738
[TBL] [Abstract][Full Text] [Related]
9. A retrospective cohort study of plasma exchange in central nervous system demyelinating events in children.
Manguinao M; Krysko KM; Maddike S; Rutatangwa A; Francisco C; Hart J; Chong J; Graves JS; Waubant E
Mult Scler Relat Disord; 2019 Oct; 35():50-54. PubMed ID: 31319355
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
[TBL] [Abstract][Full Text] [Related]
11. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.
Stellmann JP; Krumbholz M; Friede T; Gahlen A; Borisow N; Fischer K; Hellwig K; Pache F; Ruprecht K; Havla J; Kümpfel T; Aktas O; Hartung HP; Ringelstein M; Geis C; Kleinschnitz C; Berthele A; Hemmer B; Angstwurm K; Young KL; Schuster S; Stangel M; Lauda F; Tumani H; Mayer C; Zeltner L; Ziemann U; Linker RA; Schwab M; Marziniak M; Then Bergh F; Hofstadt-van Oy U; Neuhaus O; Zettl U; Faiss J; Wildemann B; Paul F; Jarius S; Trebst C; Kleiter I;
J Neurol Neurosurg Psychiatry; 2017 Aug; 88(8):639-647. PubMed ID: 28572277
[TBL] [Abstract][Full Text] [Related]
13. Neuromyelitis optica spectrum disorders with a benign course. Analysis of 544 patients.
Lana-Peixoto MA; Talim NC; Callegaro D; Marques VD; Damasceno A; Becker J; Gonçalves MVM; Sato H;
Mult Scler Relat Disord; 2023 Jul; 75():104730. PubMed ID: 37156036
[TBL] [Abstract][Full Text] [Related]
14. Influences of pregnancy on neuromyelitis optica spectrum disorders and multiple sclerosis.
Tong Y; Liu J; Yang T; Kang Y; Wang J; Zhao T; Cheng C; Fan Y
Mult Scler Relat Disord; 2018 Oct; 25():61-65. PubMed ID: 30048918
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
Viswanathan S; Wong AH; Quek AM; Yuki N
J Neuroimmunol; 2015 May; 282():92-6. PubMed ID: 25903734
[TBL] [Abstract][Full Text] [Related]
16. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
Costanzi C; Matiello M; Lucchinetti CF; Weinshenker BG; Pittock SJ; Mandrekar J; Thapa P; McKeon A
Neurology; 2011 Aug; 77(7):659-66. PubMed ID: 21813788
[TBL] [Abstract][Full Text] [Related]
17. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up.
Flechter S; Vardi J; Pollak L; Rabey JM
J Neurol Sci; 2002 May; 197(1-2):51-5. PubMed ID: 11997066
[TBL] [Abstract][Full Text] [Related]
18. Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients.
Carnero Contentti E; Soto de Castillo I; Daccach Marques V; López PA; Antunes Barreira A; Armas E; de Aquino Cruz C; Rubstein A; Lavigne Moreira C; Molina OM; Soto A; Tkachuk V
Mult Scler Relat Disord; 2018 Feb; 20():109-114. PubMed ID: 29367170
[TBL] [Abstract][Full Text] [Related]
19. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Hacohen Y; Wong YY; Lechner C; Jurynczyk M; Wright S; Konuskan B; Kalser J; Poulat AL; Maurey H; Ganelin-Cohen E; Wassmer E; Hemingway C; Forsyth R; Hennes EM; Leite MI; Ciccarelli O; Anlar B; Hintzen R; Marignier R; Palace J; Baumann M; Rostásy K; Neuteboom R; Deiva K; Lim M
JAMA Neurol; 2018 Apr; 75(4):478-487. PubMed ID: 29305608
[TBL] [Abstract][Full Text] [Related]
20. Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study.
Papais-Alvarenga RM; Vasconcelos CC; Carra A; de Castillo IS; Florentin S; Diaz de Bedoya FH; Mandler R; de Siervi LC; Pimentel ML; Alvarenga MP; Alvarenga MP; Grzesiuk AK; Gama Pereira AB; Gomes Neto AP; Velasquez C; Soublette C; Fleitas CV; Diniz DS; Armas E; Batista E; Hernandez F; Pereira FF; Siqueira HH; Cabeça H; Sanchez J; Brooks JB; Gonçalves MV; Barroso MC; Ravelo ME; Castillo MC; Ferreira ML; Rocha MS; Parolin MK; Molina O; Marinho PB; Christo PP; Brant de Souza R; Pessanha Neto S; Camargo SM; Machado SC; Neri VC; Fragoso YD; Alvarenga H; Thuler LC
PLoS One; 2015; 10(7):e0127757. PubMed ID: 26222205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
